CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 595 enrolled
Drug / intervention
Desvenlafaxine succinate sustained-release (DVS SR) +1 moredrug
Likely dose
Desvenlafaxine succinate sustained-release (DVS SR) 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00406640
NCT00406640Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, 8-Week Double-Blind Acute Phase Followed By a 6-Month Continuation Phase (Open-Label Or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women With Major Depressive Disorder

Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Dec 4, 2006·Updated Dec 28, 2023

In Brief

A Phase 3 clinical trial evaluating Desvenlafaxine succinate sustained-release (DVS SR) and Escitalopram for Depression and 2 related conditions. Completed, enrolled 595 participants across 70 sites in 6 countries.

Detailed Summary

Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major depressive disorder (MDD) who are postmenopausal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Depressive Disorder, Depressive Disorder, Major
CountriesArgentina, Chile, Colombia, Mexico, Peru, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 4, 2006
Enrollment StartDec 1, 2006
Primary CompletionFeb 1, 2008
Study CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.6 years ago

Interventions

Desvenlafaxine succinate sustained-release (DVS SR)drug

flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.

Escitalopramdrug

Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.